Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

About this update from Incannex Healthcare Inc.

Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide LOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health and medical technology market, today announced that Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex"), a clinical-stage biopharmaceutical company leading the way in developing combination medicines, has been selected as winner of the “Best New Technology Solution for Drug Development” in the 10th annual MedTech Breakthrough Awards program. The award specifically recognizes the Company’s lead drug candidate, IHL-42X, an oral fixed-dose combination therapy in development for the treatment of obstructive sleep apnea (OSA). Incannex Healthcare leverages smart drug combinations as well as strategic partnerships to develop cannabinoid-based medicines and psychedelic-based regimens. The company has pioneered the clinical development of cannabinoid combination products and psychedelic-inspired pharmaceuticals to target underlying biological pathways associated with chronic conditions that have limited, inadequate, or no approved treatment options. Drug programs include IHL-42X for OSA and IHL-675A for inflammation. Incannex is also developing an oral, synthetic psilocybin (PSX-001) treatment for generalized anxiety disorder administered in combination with psychological support. IHL-42X is the company’s lead drug development program for OSA, a disorder characterized by repeated airway collapse during sleep. The oral fixed-dose therapy combines dronabinol and acetazolamide, two active agents with complementary mechanisms that act on ventilatory stability and upper airway muscle function. The clinical impact of IHL-42X has been demonstrated in the Phase 2 RePOSA trial, which showed statistically and clinically significant improvements across key endpoints. Reductions in apnea-hypopnea index (AHI) were observed, and patients also experienced improved oxygenation, and sleep quality, as well as reductions in daytime fatigue and improvements in alertness and quality of life. Incannex Healthcare is working to develop additional innovative therapies for patients with rheumatoid arthritis (RA) and generalized anxiety disor...

View stock analysis, news, and events for Incannex Healthcare Inc.